37591-27-8

Basic information

• Product Name: 1-piperidinepropanal, alpha,alpha-dimethyl-
• Synonyms: BAS 01921129;1-piperidinepropanal, alpha,alpha-dimethyl-;2,2-dimethyl-3-piperidin-1-ylpropanal;2,2-dimethyl-3-(1-piperidyl)propanal;2,2-dimethyl-3-piperidino-propionaldehyde
• CAS NO: 37591-27-8
• Molecular Formula: C₁₀H₁₉NO
• Molecular Weight: 169.27
• Mol File: 37591-27-8.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-piperidinepropanal, alpha,alpha-dimethyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-piperidinepropanal, alpha,alpha-dimethyl-(37591-27-8)
• EPA Substance Registry System: 1-piperidinepropanal, alpha,alpha-dimethyl-(37591-27-8)

Safety Data

• Hazardous Substances Data: 37591-27-8(Hazardous Substances Data)

Usage

Physical state

Colorless to pale yellow liquid

Odor

Strong

Common uses

Fragrance ingredient in perfumes, soaps, and other cosmetic products; flavoring agent in food products

Potential applications

Pharmaceuticals; building block in organic synthesis

Safety precautions

Can cause irritation to skin, eyes, and respiratory system

Upstream product

• 110-89-4 piperidine 
• 50-00-0 formaldehyd 
• 78-84-2 isobutyraldehyde 
• 27970-32-7 3-methyl-1,3-oxazolidine 
• 673-33-6 1-piperidino-1-isobutene 

Downstream Products

• 78978-12-8 1-Phenyl-2,2-dimethyl-3-piperidino-1-propanol 
• 4667-61-2 2,2-dimethyl-3-piperidino-propan-1-ol 

Relevant articles and documents

NOVEL TRICYCLIC DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention relates to novel tricyclic derivatives having an excellent inhibitory activity on poly (ADP-ribose) polymerase, or pharmaceutically acceptable salts thereof, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The tricyclic derivatives of the present invention inhibit the activity of poly (ADP-ribose) polymerase, thereby being used for the prevention or treatment of diseases that are caused by excessive activation of PARP, in particular, neuropathic pain, neurodegenerative diseases, cardiovascular diseases, diabetic neuropathic pain, inflammatory diseases, osteoporosis, and cancer.